Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 36 entries
Sorted by: Best Match Show Resources per page
Suppressor CD4.

Gut

Khamri W, Gudd C, Liu T, Nathwani R, Krasniqi M, Azam S, Barbera T, Trovato FM, Possamai L, Triantafyllou E, Seoane RC, Lebosse F, Singanayagam A, Kumar N, Bernsmeier C, Mukherjee S, McPhail M, Weston CJ, Antoniades CG, Thursz MR.
PMID: 34344786
Gut. 2021 Aug 03; doi: 10.1136/gutjnl-2021-324071. Epub 2021 Aug 03.

OBJECTIVE: Identifying components of immuneparesis, a hallmark of chronic liver failure, is crucial for our understanding of complications in cirrhosis. Various suppressor CD4DESIGN: Flow cytometry was used to determine the proportion and immunophenotype of CD4RESULTS: Patients with AD were...

Cite
Khamri W, Gudd C, Liu T, et al. Suppressor CD4. Gut. 2021;doi: 10.1136/gutjnl-2021-324071.
Khamri, W., Gudd, C., Liu, T., Nathwani, R., Krasniqi, M., Azam, S., Barbera, T., Trovato, F. M., Possamai, L., Triantafyllou, E., Seoane, R. C., Lebosse, F., Singanayagam, A., Kumar, N., Bernsmeier, C., Mukherjee, S., McPhail, M., Weston, C. J., Antoniades, C. G., & Thursz, M. R. (2021). Suppressor CD4. Gut, . https://doi.org/10.1136/gutjnl-2021-324071
Khamri, Wafa, et al. "Suppressor CD4." Gut vol. (2021). doi: https://doi.org/10.1136/gutjnl-2021-324071
Khamri W, Gudd C, Liu T, Nathwani R, Krasniqi M, Azam S, Barbera T, Trovato FM, Possamai L, Triantafyllou E, Seoane RC, Lebosse F, Singanayagam A, Kumar N, Bernsmeier C, Mukherjee S, McPhail M, Weston CJ, Antoniades CG, Thursz MR. Suppressor CD4. Gut. 2021 Aug 03; doi: 10.1136/gutjnl-2021-324071. Epub 2021 Aug 03. PMID: 34344786.
Copy Download .nbib Format: NLM
Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.

The Journal of infectious diseases

Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Thursz M, Chemin I, Lemoine M.
PMID: 34160616
J Infect Dis. 2021 Jun 23; doi: 10.1093/infdis/jiab327. Epub 2021 Jun 23.

BACKGROUND: Prevalence of occult hepatitis B infection (OBI) and its clinical outcomes have been poorly studied in Africa.METHOD: Using the PROLIFICA cohort, we compared the prevalence of OBI between HBsAg-negative healthy adults screened from the general population (controls) and...

Cite
Ndow G, Cessay A, Cohen D, et al. Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. J Infect Dis. 2021;doi: 10.1093/infdis/jiab327.
Ndow, G., Cessay, A., Cohen, D., Shimakawa, Y., Gore, M. L., Tamba, S., Ghosh, S., Sanneh, B., Baldeh, I., Njie, R., D'Alessandro, U., Mendy, M., Thursz, M., Chemin, I., & Lemoine, M. (2021). Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. The Journal of infectious diseases, . https://doi.org/10.1093/infdis/jiab327
Ndow, Gibril, et al. "Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa." The Journal of infectious diseases vol. (2021). doi: https://doi.org/10.1093/infdis/jiab327
Ndow G, Cessay A, Cohen D, Shimakawa Y, Gore ML, Tamba S, Ghosh S, Sanneh B, Baldeh I, Njie R, D'Alessandro U, Mendy M, Thursz M, Chemin I, Lemoine M. Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa. J Infect Dis. 2021 Jun 23; doi: 10.1093/infdis/jiab327. Epub 2021 Jun 23. PMID: 34160616.
Copy Download .nbib Format: NLM
Activation and transcriptional profile of monocytes and CD8.

Journal of hepatology

Gudd CLC, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, Kumar N, Mukherjee S, Dhar A, Woollard KJ, Yone Y, Pinato DJ, Thursz MR, Goldin RD, Gore ME, Larkin J, Khamri W, Antoniades CG, Turajlic S, Possamai LA.
PMID: 33631227
J Hepatol. 2021 Jul;75(1):177-189. doi: 10.1016/j.jhep.2021.02.008. Epub 2021 Feb 22.

BACKGROUND & AIMS: Checkpoint inhibitor-related hepatitis (CPI-Hep) is an emerging clinical challenge. We aimed to gain insights into the immunopathology of CPI-Hep by comprehensively characterising myeloid and lymphoid subsets.METHODS: CPI-treated patients with or without related hepatitis (CPI-Hep; n =...

Cite
Gudd CLC, Au L, Triantafyllou E, et al. Activation and transcriptional profile of monocytes and CD8. J Hepatol. 2021;75(1):177-189doi: 10.1016/j.jhep.2021.02.008.
Gudd, C. L. C., Au, L., Triantafyllou, E., Shum, B., Liu, T., Nathwani, R., Kumar, N., Mukherjee, S., Dhar, A., Woollard, K. J., Yone, Y., Pinato, D. J., Thursz, M. R., Goldin, R. D., Gore, M. E., Larkin, J., Khamri, W., Antoniades, C. G., Turajlic, S., & Possamai, L. A. (2021). Activation and transcriptional profile of monocytes and CD8. Journal of hepatology, 75(1), 177-189. https://doi.org/10.1016/j.jhep.2021.02.008
Gudd, Cathrin L C, et al. "Activation and transcriptional profile of monocytes and CD8." Journal of hepatology vol. 75,1 (2021): 177-189. doi: https://doi.org/10.1016/j.jhep.2021.02.008
Gudd CLC, Au L, Triantafyllou E, Shum B, Liu T, Nathwani R, Kumar N, Mukherjee S, Dhar A, Woollard KJ, Yone Y, Pinato DJ, Thursz MR, Goldin RD, Gore ME, Larkin J, Khamri W, Antoniades CG, Turajlic S, Possamai LA. Activation and transcriptional profile of monocytes and CD8. J Hepatol. 2021 Jul;75(1):177-189. doi: 10.1016/j.jhep.2021.02.008. Epub 2021 Feb 22. PMID: 33631227.
Copy Download .nbib Format: NLM
Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.

Frontline gastroenterology

Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, Thursz MR, Dhar A.
PMID: 34970431
Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022.

No abstract available.

Cite
Nathwani R, Kockerling D, Mullish BH, et al. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterol. 2021;13(1):86-88doi: 10.1136/flgastro-2021-101818.
Nathwani, R., Kockerling, D., Mullish, B. H., Cole, A., Lemoine, M., Antoniades, C. G., Thursz, M. R., & Dhar, A. (2022). Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline gastroenterology, 13(1), 86-88. https://doi.org/10.1136/flgastro-2021-101818
Nathwani, Rooshi, et al. "Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections." Frontline gastroenterology vol. 13,1 (2022): 86-88. doi: https://doi.org/10.1136/flgastro-2021-101818
Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, Thursz MR, Dhar A. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022. PMID: 34970431; PMCID: PMC8666853.
Copy Download .nbib Format: NLM
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.

Journal of hepatology

Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D.
PMID: 34656649
J Hepatol. 2022 Feb;76(2):275-282. doi: 10.1016/j.jhep.2021.10.005. Epub 2021 Oct 14.

BACKGROUND & AIMS: Only a minority of excess alcohol drinkers develop cirrhosis. We developed and evaluated risk stratification scores to identify those at highest risk.METHODS: Three cohorts (GenomALC-1: n = 1,690, GenomALC-2: n = 3,037, UK Biobank: relevant n...

Cite
Whitfield JB, Schwantes-An TH, Darlay R, et al. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol. 2021;76(2):275-282doi: 10.1016/j.jhep.2021.10.005.
Whitfield, J. B., Schwantes-An, T. H., Darlay, R., Aithal, G. P., Atkinson, S. R., Bataller, R., Botwin, G., Chalasani, N. P., Cordell, H. J., Daly, A. K., Day, C. P., Eyer, F., Foroud, T., Gleeson, D., Goldman, D., Haber, P. S., Jacquet, J. M., Liang, T., Liangpunsakul, S., Masson, S., Mathurin, P., Moirand, R., McQuillin, A., Moreno, C., Morgan, M. Y., Mueller, S., Müllhaupt, B., Nagy, L. E., Nahon, P., Nalpas, B., Naveau, S., Perney, P., Pirmohamed, M., Seitz, H. K., Soyka, M., Stickel, F., Thompson, A., Thursz, M. R., Trépo, E., Morgan, T. R., Seth, D. (2022). A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of hepatology, 76(2), 275-282. https://doi.org/10.1016/j.jhep.2021.10.005
Whitfield, John B, et al. "A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers." Journal of hepatology vol. 76,2 (2022): 275-282. doi: https://doi.org/10.1016/j.jhep.2021.10.005
Whitfield JB, Schwantes-An TH, Darlay R, Aithal GP, Atkinson SR, Bataller R, Botwin G, Chalasani NP, Cordell HJ, Daly AK, Day CP, Eyer F, Foroud T, Gleeson D, Goldman D, Haber PS, Jacquet JM, Liang T, Liangpunsakul S, Masson S, Mathurin P, Moirand R, McQuillin A, Moreno C, Morgan MY, Mueller S, Müllhaupt B, Nagy LE, Nahon P, Nalpas B, Naveau S, Perney P, Pirmohamed M, Seitz HK, Soyka M, Stickel F, Thompson A, Thursz MR, Trépo E, Morgan TR, Seth D. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol. 2022 Feb;76(2):275-282. doi: 10.1016/j.jhep.2021.10.005. Epub 2021 Oct 14. PMID: 34656649.
Copy Download .nbib Format: NLM
Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.

Journal of hepatology

Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M.
PMID: 34039491
J Hepatol. 2021 Jul;75:S36-S48. doi: 10.1016/j.jhep.2020.12.005.

The transition from compensated to decompensated cirrhosis results from a complex interplay of predisposing and precipitating factors and represents an inflection point in the probability of a patient surviving. With the progression of cirrhosis, patients accumulate multiple disorders (e.g....

Cite
Gustot T, Stadlbauer V, Laleman W, et al. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol. 2021;75:S36-S48doi: 10.1016/j.jhep.2020.12.005.
Gustot, T., Stadlbauer, V., Laleman, W., Alessandria, C., & Thursz, M. (2021). Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. Journal of hepatology, 75S36-S48. https://doi.org/10.1016/j.jhep.2020.12.005
Gustot, Thierry, et al. "Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events." Journal of hepatology vol. 75 (2021): S36-S48. doi: https://doi.org/10.1016/j.jhep.2020.12.005
Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol. 2021 Jul;75:S36-S48. doi: 10.1016/j.jhep.2020.12.005. PMID: 34039491.
Copy Download .nbib Format: NLM
Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination.

World journal of hepatology

Tanwar S, Thursz M.
PMID: 21160984
World J Hepatol. 2010 Mar 27;2(3):136-8. doi: 10.4254/wjh.v2.i3.136.

Hepatitis B vaccination is successful in 95% of individuals. In the remainder, despite repeated attempts, immunization often remains unsuccessful. 'Non-response' leaves the individual susceptible to infection. Various strategies have been employed to overcome this. These include the use of...

Cite
Tanwar S, Thursz M. Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. World J Hepatol. 2010;2(3):136-8doi: 10.4254/wjh.v2.i3.136.
Tanwar, S., & Thursz, M. (2010). Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. World journal of hepatology, 2(3), 136-8. https://doi.org/10.4254/wjh.v2.i3.136
Tanwar, Sudeep, and Thursz, Mark. "Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination." World journal of hepatology vol. 2,3 (2010): 136-8. doi: https://doi.org/10.4254/wjh.v2.i3.136
Tanwar S, Thursz M. Granulocyte colony-stimulating factor as a novel adjunct to improve hepatitis B vaccination. World J Hepatol. 2010 Mar 27;2(3):136-8. doi: 10.4254/wjh.v2.i3.136. PMID: 21160984; PMCID: PMC2999275.
Copy Download .nbib Format: NLM
Get active.

Journal of hepatology

Thursz M.
PMID: 22173036
J Hepatol. 2012 Jan;56(1):5-6. doi: 10.1016/j.jhep.2011.09.005.

No abstract available.

Cite
Thursz M. Get active. J Hepatol. 2012;56(1):5-6doi: 10.1016/j.jhep.2011.09.005.
Thursz, M. (2012). Get active. Journal of hepatology, 56(1), 5-6. https://doi.org/10.1016/j.jhep.2011.09.005
Thursz, Mark. "Get active." Journal of hepatology vol. 56,1 (2012): 5-6. doi: https://doi.org/10.1016/j.jhep.2011.09.005
Thursz M. Get active. J Hepatol. 2012 Jan;56(1):5-6. doi: 10.1016/j.jhep.2011.09.005. PMID: 22173036.
Copy Download .nbib Format: NLM
The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience.

Hepatitis research and treatment

Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M.
PMID: 22114737
Hepat Res Treat. 2011;2011:524027. doi: 10.1155/2011/524027. Epub 2011 Oct 30.

Background & Aims. Assess the clinical utility of the Prati criteria and normal ALT ( 6 log copies/ml and normal ALT, who in fact had moderate/severe fibrosis on liver biopsy. HBeAg(-) group: 10 patients with normal ALT and moderate/severe...

Cite
Malik R, Kennedy P, Suri D, et al. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat. 2011;2011:524027doi: 10.1155/2011/524027.
Malik, R., Kennedy, P., Suri, D., Brown, A., Goldin, R., Main, J., Thomas, H., & Thursz, M. (2011). The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepatitis research and treatment, 2011524027. https://doi.org/10.1155/2011/524027
Malik, Raza, et al. "The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience." Hepatitis research and treatment vol. 2011 (2011): 524027. doi: https://doi.org/10.1155/2011/524027
Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat. 2011;2011:524027. doi: 10.1155/2011/524027. Epub 2011 Oct 30. PMID: 22114737; PMCID: PMC3205689.
Copy Download .nbib Format: NLM
Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.

Frontline gastroenterology

Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, Thursz MR, Dhar A.
PMID: 34970431
Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022.

No abstract available.

Cite
Nathwani R, Kockerling D, Mullish BH, et al. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterol. 2021;13(1):86-88doi: 10.1136/flgastro-2021-101818.
Nathwani, R., Kockerling, D., Mullish, B. H., Cole, A., Lemoine, M., Antoniades, C. G., Thursz, M. R., & Dhar, A. (2022). Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline gastroenterology, 13(1), 86-88. https://doi.org/10.1136/flgastro-2021-101818
Nathwani, Rooshi, et al. "Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections." Frontline gastroenterology vol. 13,1 (2022): 86-88. doi: https://doi.org/10.1136/flgastro-2021-101818
Nathwani R, Kockerling D, Mullish BH, Cole A, Lemoine M, Antoniades CG, Thursz MR, Dhar A. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections. Frontline Gastroenterol. 2021 Mar 11;13(1):86-88. doi: 10.1136/flgastro-2021-101818. eCollection 2022. PMID: 34970431; PMCID: PMC8666853.
Copy Download .nbib Format: NLM
Dispersal of the Invasive Pasture Pest Heteronychus arator into Areas of Low Population Density: Effects of Sex and Season, and Implications for Pest Management.

Frontiers in plant science

Mansfield S, Gerard PJ, Hurst MR, Townsend RJ, Wilson DJ, van Koten C.
PMID: 27617018
Front Plant Sci. 2016 Aug 26;7:1278. doi: 10.3389/fpls.2016.01278. eCollection 2016.

African black beetle, Heteronychus arator (Scarabaeidae), is an exotic pest of pastures in northern New Zealand. Both adults and larvae feed on pasture grasses. Adults disperse by walking (short range) or flying (long range). Dispersal flights are triggered by...

Cite
Mansfield S, Gerard PJ, Hurst MR, et al. Dispersal of the Invasive Pasture Pest Heteronychus arator into Areas of Low Population Density: Effects of Sex and Season, and Implications for Pest Management. Front Plant Sci. 2016;7:1278doi: 10.3389/fpls.2016.01278.
Mansfield, S., Gerard, P. J., Hurst, M. R., Townsend, R. J., Wilson, D. J., & van Koten, C. (2016). Dispersal of the Invasive Pasture Pest Heteronychus arator into Areas of Low Population Density: Effects of Sex and Season, and Implications for Pest Management. Frontiers in plant science, 71278. https://doi.org/10.3389/fpls.2016.01278
Mansfield, Sarah, et al. "Dispersal of the Invasive Pasture Pest Heteronychus arator into Areas of Low Population Density: Effects of Sex and Season, and Implications for Pest Management." Frontiers in plant science vol. 7 (2016): 1278. doi: https://doi.org/10.3389/fpls.2016.01278
Mansfield S, Gerard PJ, Hurst MR, Townsend RJ, Wilson DJ, van Koten C. Dispersal of the Invasive Pasture Pest Heteronychus arator into Areas of Low Population Density: Effects of Sex and Season, and Implications for Pest Management. Front Plant Sci. 2016 Aug 26;7:1278. doi: 10.3389/fpls.2016.01278. eCollection 2016. PMID: 27617018; PMCID: PMC4999450.
Copy Download .nbib Format: NLM
Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.

The International journal on drug policy

Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M.
PMID: 34624732
Int J Drug Policy. 2021 Oct 05;99:103458. doi: 10.1016/j.drugpo.2021.103458. Epub 2021 Oct 05.

BACKGROUND: Compared to other countries in sub-Saharan Africa, Tanzania has a relatively progressive illicit drug harm reduction (HR) policy, through a predominantly opioid substitution therapy-based programme. However, access to hepatitis C virus (HCV) diagnosis and curative direct acting antiviral...

Cite
Mohamed Z, Scott N, Nayagam S, et al. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. Int J Drug Policy. 2021;99:103458doi: 10.1016/j.drugpo.2021.103458.
Mohamed, Z., Scott, N., Nayagam, S., Rwegasha, J., Mbwambo, J., Thursz, M. R., Brown, A. S., Hellard, M., & Lemoine, M. (2021). Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. The International journal on drug policy, 99103458. https://doi.org/10.1016/j.drugpo.2021.103458
Mohamed, Zameer, et al. "Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania." The International journal on drug policy vol. 99 (2021): 103458. doi: https://doi.org/10.1016/j.drugpo.2021.103458
Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania. Int J Drug Policy. 2021 Oct 05;99:103458. doi: 10.1016/j.drugpo.2021.103458. Epub 2021 Oct 05. PMID: 34624732.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 36 entries